Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Krzysztof Ostaszewski
Observed names:
K. Ostaszewski,
Ostaszewski, Krzysztof
Institution:
The Maria Sklodowska-Curie National Research Institute of Oncology
Observed institutions:
Wojskowy Instytut Medycyny Lotniczej,
Wojskowy Instytut Medyczny,
The Maria Sklodowska-Curie National Research Institute of Oncology
ORCID:
0000-0002-9679-0523
Observed ORCID:
0000-0002-9679-0523
OpenAlex ID:
A5012961244
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment
2023
·
Bożena Cybulska-Stopa
, Karolina Piejko
, et al.
·
Melanoma Research
·
17
Efficacy of Neoadjuvant Targeted Therapy for Borderline Resectable III B-D or IV Stage BRAF V600 Mutation-Positive Melanoma
2021
·
Anna M. Czarnecka
, Krzysztof Ostaszewski
, et al.
·
Cancers
·
15
PDF
Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Cancers
·
10
PDF
Long-Term Outcomes of Targeted Therapy after First-Line Immunotherapy in BRAF-Mutated Advanced Cutaneous Melanoma Patients—Real-World Evidence
2022
·
Paweł Rogala
, Anna M. Czarnecka
, et al.
·
Journal of Clinical Medicine
·
10
PDF
Long‐term efficacy of neoadjuvant–adjuvant targeted therapy in borderline resectable stage IIIB–D and IV melanoma
2024
·
Anna M. Czarnecka
, Krzysztof Ostaszewski
, et al.
·
Cancer
·
5
PDF
Molecular and Clinicopathological Biomarkers in the Neoadjuvant Treatment of Patients with Advanced Resectable Melanoma
2024
·
Piotr J. Błoński
, Anna M. Czarnecka
, et al.
·
Biomedicines
·
5
PDF
Preoperative-postoperative immunotherapy as treatment of borderline resectable and oligoprogressive stage III B-D and IV melanoma
2024
·
Anna M. Czarnecka
, Krzysztof Ostaszewski
, et al.
·
European Journal of Surgical Oncology
·
3
Discontinuation of Immune Checkpoint Inhibition in Patients with Advanced Unresectable Melanoma Achieving CR, PR, or SD
2025
·
Anna M. Czarnecka
, Paweł Teterycz
, et al.
·
Targeted Oncology
·
2
PDF
1115P Comparison of efficacy and toxicity of dabrafenib/trametinib versus vemurafenib/cobimetinib therapy in routine medical practice: Eight years of BRAF/MEK inhibitor use in routine clinical practice
2023
·
K. Piejko
, B. Cybulska-Stopa
, et al.
·
Annals of Oncology
·
2
PDF
Sequential treatment with targeted and immune checkpoint inhibitor therapies in patients with BRAF positive metastatic melanoma: Real-world data.
2022
·
Bozena Cybulska-Stopa
, Anna Malgorzata Czarnecka
, et al.
·
Journal of Clinical Oncology
·
2
1682P Outcomes of first-, second- and third-line treatment with all available combinations of BRAF plus MEK inhibitors in advanced melanoma patients: A real-world study
2025
·
A.M. Czarnecka
, P. Blonski
, et al.
·
Annals of Oncology
·
1
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study
2023
·
A.M. Czarnecka
, P. Teterycz
, et al.
·
Annals of Oncology
·
1
PDF
835P Efficacy of checkpoint inhibitors and targeted therapy depending on the line of treatment in patients with advanced / metastatic melanoma
2022
·
B. Cybulska-Stopa
, A.M. Czarnecka
, et al.
·
Annals of Oncology
·
1
Comparison of real-world effectiveness of all approved BRAF/MEK inhibitor combinations in BRAF -mutant melanoma patients.
2026
·
Anna Malgorzata Czarnecka
, Piotr Jan Blonski
, et al.
·
Journal of Clinical Oncology
PDF
Outcomes of systemic treatment in advanced melanoma after progression on anti–PD-1 therapy: a real-world study with literature review
2026
·
Piotr J. Błoński
, Krzysztof Ostaszewski
, et al.
·
DOAJ (DOAJ: Directory of Open Access Journals)
Cardiac tumor as first presentation of melanoma
2025
·
Magdalena K. Zielińska
, Monika Dudzisz-Śledź
, et al.
·
Oncology in Clinical Practice
PDF
Treatment with avelumab of patients with inoperable and metastatic Merkel cell carcinoma: the results of multicenter study
2025
·
M. Dudzisz-Sledz
, P. Blonski
, et al.
·
EJC Skin Cancer
The Efficacy of Encorafenib with Binimetinib in the Treatment of Patients with Advanced Melanoma - Real-world Evidence
2025
·
A.M. Czarnecka
, P. Błoński
, et al.
·
EJC Skin Cancer
Deescalation of immunotherapy in metastatic melanoma patients with scheduled drug holidays
2025
·
A.M. Czarnecka
, P. Teterycz
, et al.
·
EJC Skin Cancer
PDF
Defining Textbook Outcomes in patients with locally advanced melanoma treated with neoadjuvant systemic therapy and surgery
2024
·
P. Rutkowski
, P. Blonski
, et al.
·
European Journal of Surgical Oncology
Surgical Textbook Outcomes in the Era of Neoadjuvant Systemic Treatment for Skin Cancers
2024
·
Piotr Jan Błoński
, Piotr Rutkowski
, et al.
·
Journal of Clinical Medicine
PDF
Efficacy of neoadjuvant followed by adjuvant therapy in marginally resectable stage IIIB-D or IV melanoma
2024
·
Anna Czarnecka
, Krzysztof Ostaszewski
, et al.
·
European Journal of Surgical Oncology
Is the BRAF mutation still an unfavorable risk factor in patients with metastatic melanoma in the era of modern therapies?
2022
·
Bozena Cybulska-Stopa
, Anna Malgorzata Czarnecka
, et al.
·
Journal of Clinical Oncology
Efficacy of neoadjuvant therapy of stage IIIB-D or IV melanoma – real world evidence
2022
·
Piotr Rutkowski
, Krzysztof Ostaszewski
, et al.
·
European Journal of Surgical Oncology
1087P The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
2021
·
B. Cybulska-Stopa
, A.M. Czarnecka
, et al.
·
Annals of Oncology
Show more works
View as search
Works count:
29
Citation count:
74
H-index:
5
I10-index:
4
Year
Topic
Type